Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Cardiac Tumor | Research

The benign nature and rare occurrence of cardiac myxoma as a possible consequence of the limited cardiac proliferative/ regenerative potential: a systematic review

Authors: Ovais Shafi, Ghazia Siddiqui, Hassam A. Jaffry

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Cardiac Myxoma is a primary tumor of heart. Its origins, rarity of the occurrence of primary cardiac tumors and how it may be related to limited cardiac regenerative potential, are not yet entirely known. This study investigates the key cardiac genes/ transcription factors (TFs) and signaling pathways to understand these important questions.

Methods

Databases including PubMed, MEDLINE, and Google Scholar were searched for published articles without any date restrictions, involving cardiac myxoma, cardiac genes/TFs/signaling pathways and their roles in cardiogenesis, proliferation, differentiation, key interactions and tumorigenesis, with focus on cardiomyocytes.

Results

The cardiac genetic landscape is governed by a very tight control between proliferation and differentiation-related genes/TFs/pathways. Cardiac myxoma originates possibly as a consequence of dysregulations in the gene expression of differentiation regulators including Tbx5, GATA4, HAND1/2, MYOCD, HOPX, BMPs. Such dysregulations switch the expression of cardiomyocytes into progenitor-like state in cardiac myxoma development by dysregulating Isl1, Baf60 complex, Wnt, FGF, Notch, Mef2c and others.

The Nkx2–5 and MSX2 contribute predominantly to both proliferation and differentiation of Cardiac Progenitor Cells (CPCs), may possibly serve roles based on the microenvironment and the direction of cell circuitry in cardiac tumorigenesis. The Nkx2–5 in cardiac myxoma may serve to limit progression of tumorigenesis as it has massive control over the proliferation of CPCs. The cardiac cell type-specific genetic programming plays governing role in controlling the tumorigenesis and regenerative potential.

Conclusion

The cardiomyocytes have very limited proliferative and regenerative potential. They survive for long periods of time and tightly maintain the gene expression of differentiation genes such as Tbx5, GATA4 that interact with tumor suppressors (TS) and exert TS like effect. The total effect such gene expression exerts is responsible for the rare occurrence and benign nature of primary cardiac tumors. This prevents the progression of tumorigenesis. But this also limits the regenerative and proliferative potential of cardiomyocytes. Cardiac Myxoma develops as a consequence of dysregulations in these key genes which revert the cells towards progenitor-like state, hallmark of CM. The CM development in carney complex also signifies the role of TS in cardiac cells.

Singhal P, Luk A, Rao V, Butany J. Molecular basis of cardiac myxomas. Int J Mol Sci. 2014;15(1):1315–37. https://doi.org/10.3390/ijms15011315.CrossRefPubMedPubMedCentral

Nugraha B, Buono MF, von Boehmer L, Hoerstrup SP, Emmert MY. Human cardiac organoids for disease modeling. Clin Pharmacol Ther. 2019;105(1):79–85. https://doi.org/10.1002/cpt.1286.CrossRefPubMed

Mazzola M, Di Pasquale E. Toward cardiac regeneration: combination of pluripotent stem cell-based therapies and bioengineering strategies. Front Bioeng Biotechnol. 2020;8:455. https://doi.org/10.3389/fbioe.2020.00455.CrossRefPubMedPubMedCentral

Verjans R, van Bilsen M, Schroen B. Reviewing the limitations of adult mammalian cardiac regeneration: noncoding RNAs as regulators of Cardiomyogenesis. Biomolecules. 2020;10(2):262. https://doi.org/10.3390/biom10020262.CrossRefPubMedPubMedCentral

Hashimoto H, Olson EN, Bassel-Duby R. Therapeutic approaches for cardiac regeneration and repair. Nat Rev Cardiol. 2018;15(10):585–600. https://doi.org/10.1038/s41569-018-0036-6.CrossRefPubMedPubMedCentral

Puente BN, Kimura W, Muralidhar SA, Moon J, Amatruda JF, Phelps KL, et al. The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response. Cell. 2014;157(3):565–79. https://doi.org/10.1016/j.cell.2014.03.032.CrossRefPubMedPubMedCentral

Breckwoldt K, Weinberger F, Eschenhagen T. Heart regeneration. Biochim Biophys Acta. 2016;1863(7 Pt B):1749–59. https://doi.org/10.1016/j.bbamcr.2015.11.010.CrossRefPubMed

Zhang Y, Mignone J, MacLellan WR. Cardiac regeneration and stem cells. Physiol Rev. 2015;95(4):1189–204. https://doi.org/10.1152/physrev.00021.2014.CrossRefPubMedPubMedCentral

Doevendans PA, van Bilsen M. Transcription factors and the cardiac gene programme. Int J Biochem Cell Biol. 1996;28(4):387–403. https://doi.org/10.1016/1357-2725(95)00145-x.CrossRefPubMed

10.

Hong JH, Zhang HG. Transcription factors involved in the development and prognosis of cardiac remodeling. Front Pharmacol. 2022;(13):828549. https://doi.org/10.3389/fphar.2022.828549.

11.

Zhu L, Liu K, Feng Q, Liao Y. Cardiac organoids: a 3D Technology for Modeling Heart Development and Disease. Stem Cell Rev Rep. 2022; https://doi.org/10.1007/s12015-022-10385-1.

12.

Filippo Buono M, von Boehmer L, Strang J, Hoerstrup SP, Emmert MY, Nugraha B. Human cardiac organoids for modeling genetic cardiomyopathy. Cells. 2020;9(7):1733. https://doi.org/10.3390/cells9071733.CrossRefPubMedPubMedCentral

13.

Drakhlis L, Devadas SB, Zweigerdt R. Generation of heart-forming organoids from human pluripotent stem cells. Nat Protoc. 2021;16(12):5652–72. https://doi.org/10.1038/s41596-021-00629-8.CrossRefPubMed

14.

Petris AO, Alexandrescu DM, Costache II. Cardiac tumors. Rev Med Chir Soc Med Nat Iasi. 2014;118(2):289–92.PubMed

15.

Rahouma M, Arisha MJ, Elmously A, El-Sayed Ahmed MM, Spadaccio C, Mehta K, et al. Cardiac tumors prevalence and mortality: a systematic review and meta-analysis. Int J Surg. 2020;76:178–89. https://doi.org/10.1016/j.ijsu.2020.02.039.CrossRefPubMed

16.

Hori Y, Tanimoto Y, Takahashi S, Furukawa T, Koshiba-Takeuchi K, Takeuchi JK. Important cardiac transcription factor genes are accompanied by bidirectional long non-coding RNAs. BMC Genomics. 2018;19(1):967. https://doi.org/10.1186/s12864-018-5233-5.CrossRefPubMedPubMedCentral

17.

Voges HK, Mills RJ, Elliott DA, Parton RG, Porrello ER, Hudson JE. Development of a human cardiac organoid injury model reveals innate regenerative potential. Development. 2017;144(6):1118–27. https://doi.org/10.1242/dev.143966.CrossRefPubMed

18.

Scalise M, Marino F, Salerno L, Cianflone E, Molinaro C, Salerno N, et al. From spheroids to organoids: the next generation of model Systems of Human Cardiac Regeneration in a dish. Int J Mol Sci. 2021;22(24):13180. https://doi.org/10.3390/ijms222413180.CrossRefPubMedPubMedCentral

19.

Leja MJ, Shah DJ, Reardon MJ. Primary cardiac tumors. Tex Heart Inst J. 2011;38(3):261–2.PubMedPubMedCentral

20.

Nakada Y, Kimura W, Sadek HA. Defining the limit of embryonic heart regeneration. Circulation. 2015;132(2):77–8. https://doi.org/10.1161/CIRCULATIONAHA.115.017070.CrossRefPubMed

21.

Ghiroldi A, Piccoli M, Cirillo F, Monasky MM, Ciconte G, Pappone C, et al. Cell-based therapies for cardiac regeneration: a comprehensive review of past and ongoing strategies. Int J Mol Sci. 2018;19(10):3194. https://doi.org/10.3390/ijms19103194.CrossRefPubMedPubMedCentral

22.

Caspi O, Gepstein L. Insights from the third dimension: cardiac organoids help identify regenerative pathways. Cell Stem Cell. 2019;24(6):833–4. https://doi.org/10.1016/j.stem.2019.05.012.CrossRefPubMed

23.

Varzideh F, Pahlavan S, Ansari H, Halvaei M, Kostin S, Feiz MS, et al. Human cardiomyocytes undergo enhanced maturation in embryonic stem cell-derived organoid transplants. Biomaterials. 2019;192:537–50. https://doi.org/10.1016/j.biomaterials.2018.11.033.CrossRefPubMed

24.

Cho J, Lee H, Rah W, Chang HJ, Yoon YS. From engineered heart tissue to cardiac organoid. Theranostics. 2022;12(6):2758–72. https://doi.org/10.7150/thno.67661.CrossRefPubMedPubMedCentral

25.

Gao R, Liang X, Cheedipudi S, Cordero J, Jiang X, Zhang Q, et al. Pioneering function of Isl1 in the epigenetic control of cardiomyocyte cell fate. Cell Res. 2019;29(6):486–501. https://doi.org/10.1038/s41422-019-0168-1.CrossRefPubMedPubMedCentral

26.

Cai CL, Liang X, Shi Y, Chu PH, Pfaff SL, Chen J, et al. Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev Cell. 2003;5(6):877–89. https://doi.org/10.1016/s1534-5807(03)00363-0.CrossRefPubMedPubMedCentral

27.

Pandur P, Sirbu IO, Kühl SJ, Philipp M, Kühl M. Islet1-expressing cardiac progenitor cells: a comparison across species. Dev Genes Evol. 2013;223(1–2):117–29. https://doi.org/10.1007/s00427-012-0400-1.CrossRefPubMed

28.

Hatzistergos KE, Durante MA, Valasaki K, Wanschel ACBA, Harbour JW, Hare JM. A novel cardiomyogenic role for Isl1⁺ neural crest cells in the inflow tract. Sci Adv. 2020;6(49):eaba9950. https://doi.org/10.1126/sciadv.aba9950.CrossRefPubMedPubMedCentral

29.

Quaranta R, Fell J, Rühle F, Rao J, Piccini I, Araúzo-Bravo MJ, et al. Revised roles of ISL1 in a hES cell-based model of human heart chamber specification. Elife. 2018;7:e31706. https://doi.org/10.7554/eLife.31706.CrossRefPubMedPubMedCentral

30.

Golzio C, Havis E, Daubas P, Nuel G, Babarit C, Munnich A, et al. ISL1 directly regulates FGF10 transcription during human cardiac outflow formation. PLoS One. 2012;7(1):e30677. https://doi.org/10.1371/journal.pone.0030677.CrossRefPubMedPubMedCentral

31.

Khatami M, Heidari MM, Kazeminasab F, Zare BR. Identification of a novel non-sense mutation in TBX5 gene in pediatric patients with congenital heart defects. J Cardiovasc Thorac Res. 2018;10(1):41–5. https://doi.org/10.15171/jcvtr.2018.07.CrossRefPubMedPubMedCentral

32.

Genead R, Danielsson C, Andersson AB, Corbascio M, Franco-Cereceda A, Sylvén C, et al. Islet-1 cells are cardiac progenitors present during the entire lifespan: from the embryonic stage to adulthood. Stem Cells Dev. 2010;19(10):1601–15. https://doi.org/10.1089/scd.2009.0483.CrossRefPubMed

33.

Barreto S, Hamel L, Schiatti T, Yang Y, George V. Cardiac progenitor cells from stem cells: learning from genetics and biomaterials. Cells. 2019;8(12):1536. https://doi.org/10.3390/cells8121536.CrossRefPubMedPubMedCentral

34.

Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodard S, et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005;433(7026):647–53. https://doi.org/10.1038/nature03215.CrossRefPubMedPubMedCentral

35.

Bartulos O, Zhuang ZW, Huang Y, Mikush N, Suh C, Bregasi A, et al. ISL1 cardiovascular progenitor cells for cardiac repair after myocardial infarction. JCI Insight. 2016;1(10):e80920. https://doi.org/10.1172/jci.insight.80920.CrossRefPubMedPubMedCentral

36.

Zhou B, von Gise A, Ma Q, Rivera-Feliciano J, Pu WT. Nkx2-5- and Isl1-expressing cardiac progenitors contribute to proepicardium. Biochem Biophys Res Commun. 2008;375(3):450–3. https://doi.org/10.1016/j.bbrc.2008.08.044.CrossRefPubMedPubMedCentral

37.

Dodou E, Verzi MP, Anderson JP, Xu SM, Black BL. Mef2c is a direct transcriptional target of ISL1 and GATA factors in the anterior heart field during mouse embryonic development. Development. 2004;131(16):3931–42. https://doi.org/10.1242/dev.01256.CrossRefPubMed

38.

Ma Q, Zhou B, Pu WT. Reassessment of Isl1 and Nkx2-5 cardiac fate maps using a Gata4-based reporter of Cre activity. Dev Biol. 2008;323(1):98–104. https://doi.org/10.1016/j.ydbio.2008.08.013.CrossRefPubMedPubMedCentral

39.

Kelly RG, Buckingham ME, Moorman AF. Heart fields and cardiac morphogenesis. Cold Spring Harb Perspect Med. 2014;4(10):a015750. https://doi.org/10.1101/cshperspect.a015750.CrossRefPubMedPubMedCentral

40.

Scalise M, Torella M, Marino F, Ravo M, Giurato G, Vicinanza C, et al. Atrial myxomas arise from multipotent cardiac stem cells. Eur Heart J. 2020;41(45):4332–45. https://doi.org/10.1093/eurheartj/ehaa156.CrossRefPubMedPubMedCentral

41.

Dorn T, Goedel A, Lam JT, Haas J, Tian Q, Herrmann F, et al. Direct nkx2-5 transcriptional repression of isl1 controls cardiomyocyte subtype identity. Stem Cells. 2015;33(4):1113–29. https://doi.org/10.1002/stem.1923.CrossRefPubMed

42.

Colombo S, de Sena-Tomás C, George V, Werdich AA, Kapur S, MacRae CA, et al. Nkx genes establish second heart field cardiomyocyte progenitors at the arterial pole and pattern the venous pole through Isl1 repression. Development. 2018;145(3):dev161497. https://doi.org/10.1242/dev.161497.CrossRefPubMedPubMedCentral

43.

Gay F, Anglade I, Gong Z, Salbert G. The LIM/homeodomain protein islet-1 modulates estrogen receptor functions. Mol Endocrinol. 2000;14(10):1627–48. https://doi.org/10.1210/mend.14.10.0538.CrossRefPubMed

44.

Davis AM, Seney ML, Walker HJ, Tobet SA. Differential colocalization of Islet-1 and estrogen receptor alpha in the murine preoptic area and hypothalamus during development. Endocrinology. 2004;145(1):360–6. https://doi.org/10.1210/en.2003-0996.CrossRefPubMed

45.

Miranda-Carboni GA, Guemes M, Bailey S, Anaya E, Corselli M, Peault B, et al. GATA4 regulates estrogen receptor-alpha-mediated osteoblast transcription. Mol Endocrinol. 2011;25(7):1126–36. https://doi.org/10.1210/me.2010-0463.CrossRefPubMedPubMedCentral

46.

Ye Y, Chen X, Zhang W. Mammalian SWI/SNF chromatin remodeling complexes in embryonic stem cells: regulating the balance between pluripotency and differentiation. Front Cell Dev Biol. 2021;8:626383. https://doi.org/10.3389/fcell.2020.626383.CrossRefPubMedPubMedCentral

47.

George RM, Firulli AB. Epigenetics and heart development. Front Cell Dev Biol. 2021;9:637996. https://doi.org/10.3389/fcell.2021.637996.CrossRefPubMedPubMedCentral

48.

Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu Rev Biochem. 2009;78:273–304. https://doi.org/10.1146/annurev.biochem.77.062706.153223.CrossRefPubMed

49.

Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, et al. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Mol Cell Biol. 2013;33(15):3011–25. https://doi.org/10.1128/MCB.01443-12.CrossRefPubMedPubMedCentral

50.

Javaid S, Zhang J, Anderssen E, Black JC, Wittner BS, Tajima K, et al. Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1. Cell Rep. 2013;5(6):1679–89. https://doi.org/10.1016/j.celrep.2013.11.034.CrossRefPubMedPubMedCentral

51.

Oh J, Sohn DH, Ko M, Chung H, Jeon SH, Seong RH. BAF60a interacts with p53 to recruit the SWI/SNF complex. J Biol Chem. 2008;283(18):11924–34. https://doi.org/10.1074/jbc.M705401200.CrossRefPubMed

52.

Cai W, Albini S, Wei K, Willems E, Guzzo RM, Tsuda M, et al. Coordinate Nodal and BMP inhibition directs Baf60c-dependent cardiomyocyte commitment. Genes Dev. 2013;27(21):2332–44. https://doi.org/10.1101/gad.225144.113.CrossRefPubMedPubMedCentral

53.

Chen L, Fulcoli FG, Ferrentino R, Martucciello S, Illingworth EA, Baldini A. Transcriptional control in cardiac progenitors: Tbx1 interacts with the BAF chromatin remodeling complex and regulates Wnt5a. PLoS Genet. 2012;8(3):e1002571. https://doi.org/10.1371/journal.pgen.1002571.CrossRefPubMedPubMedCentral

54.

Hota SK, Johnson JR, Verschueren E, Thomas R, Blotnick AM, Zhu Y, et al. Dynamic BAF chromatin remodeling complex subunit inclusion promotes temporally distinct gene expression programs in cardiogenesis. Development. 2019;146(19):dev174086. https://doi.org/10.1242/dev.174086.CrossRefPubMedPubMedCentral

55.

Hatcher CJ, Kim MS, Mah CS, Goldstein MM, Wong B, Mikawa T, et al. TBX5 transcription factor regulates cell proliferation during cardiogenesis. Dev Biol. 2001;230(2):177–88. https://doi.org/10.1006/dbio.2000.0134.CrossRefPubMed

56.

Akazawa H, Komuro I. Cardiac transcription factor Csx/Nkx2-5: its role in cardiac development and diseases. Pharmacol Ther. 2005;107(2):252–68. https://doi.org/10.1016/j.pharmthera.2005.03.005.CrossRefPubMed

57.

Bouveret R, Waardenberg AJ, Schonrock N, Ramialison M, Doan T, de Jong D, et al. NKX2-5 mutations causative for congenital heart disease retain functionality and are directed to hundreds of targets. Elife. 2015;4:e06942. https://doi.org/10.7554/eLife.06942.CrossRefPubMedPubMedCentral

58.

Clark CD, Lee KH. Second heart field-specific expression of Nkx2-5 requires promoter proximal interaction with Srf. Mech Dev. 2020;162:103615. https://doi.org/10.1016/j.mod.2020.103615.CrossRefPubMedPubMedCentral

59.

Cambier L, Plate M, Sucov HM, Pashmforoush M. Nkx2-5 regulates cardiac growth through modulation of Wnt signaling by R-spondin3. Development. 2014;141(15):2959–71. https://doi.org/10.1242/dev.103416.CrossRefPubMedPubMedCentral

60.

Liu Z, Li T, Liu Y, Jia Z, Li Y, Zhang C, et al. WNT signaling promotes Nkx2.5 expression and early cardiomyogenesis via downregulation of Hdac1. Biochim Biophys Acta. 2009;1793(2):300–11. https://doi.org/10.1016/j.bbamcr.2008.08.013.CrossRefPubMed

61.

Li H, Wang J, Huang K, Zhang T, Gao L, Yang S, et al. Front Oncol. 2021;11:648045. https://doi.org/10.3389/fonc.2021.648045.CrossRefPubMedPubMedCentral

62.

Komuro I, Izumo S. Csx: a murine homeobox-containing gene specifically expressed in the developing heart. Proc Natl Acad Sci U S A. 1993;90(17):8145–9. https://doi.org/10.1073/pnas.90.17.8145.CrossRefPubMedPubMedCentral

63.

Chen L, Fulcoli FG, Tang S, Baldini A. Tbx1 regulates proliferation and differentiation of multipotent heart progenitors. Circ Res. 2009;105(9):842–51. https://doi.org/10.1161/CIRCRESAHA.109.200295.CrossRefPubMedPubMedCentral

64.

Hou D, Guan Y, Liu J, Xiao Z, Ouyang Y, Yu Y, et al. Cloning and characterization of the NPCEDRG gene promoter. Mol Cell Biochem. 2011;346(1–2):1–10. https://doi.org/10.1007/s11010-010-0584-5.CrossRefPubMed

65.

Behrens AN, Iacovino M, Lohr JL, Ren Y, Zierold C, Harvey RP, et al. Nkx2-5 mediates differential cardiac differentiation through interaction with Hoxa10. Stem Cells Dev. 2013;22(15):2211–20. https://doi.org/10.1089/scd.2012.0611.CrossRefPubMedPubMedCentral

66.

Jamali M, Karamboulas C, Rogerson PJ, Skerjanc IS. BMP signaling regulates Nkx2-5 activity during cardiomyogenesis. FEBS Lett. 2001;509(1):126–30. https://doi.org/10.1016/s0014-5793(01)03151-9.CrossRefPubMed

67.

Wang J, Jin Y, Cattini PA. Expression of the cardiac maintenance and survival factor FGF-16 gene is regulated by Csx/Nkx2.5 and is an early target of doxorubicin cardiotoxicity. DNA Cell Biol. 2017;36(2):117–26. https://doi.org/10.1089/dna.2016.3507.CrossRefPubMed

68.

Watanabe Y, Zaffran S, Kuroiwa A, Higuchi H, Ogura T, Harvey RP, et al. Fibroblast growth factor 10 gene regulation in the second heart field by Tbx1, Nkx2-5, and Islet1 reveals a genetic switch for down-regulation in the myocardium. Proc Natl Acad Sci U S A. 2012;109(45):18273–80. https://doi.org/10.1073/pnas.1215360109.CrossRefPubMedPubMedCentral

69.

Kodama H, Hirotani T, Suzuki Y, Ogawa S, Yamazaki K. Cardiomyogenic differentiation in cardiac myxoma expressing lineage-specific transcription factors. Am J Pathol. 2002;161(2):381–9. https://doi.org/10.1016/S0002-9440(10)64193-4.CrossRefPubMedPubMedCentral

70.

Serpooshan V, Liu YH, Buikema JW, Galdos FX, Chirikian O, Paige S, et al. Nkx2.5+ Cardiomyoblasts contribute to Cardiomyogenesis in the neonatal heart. Sci Rep. 2017;7(1):12590. https://doi.org/10.1038/s41598-017-12869-4.CrossRefPubMedPubMedCentral

71.

Yannarelli G, Pacienza N, Montanari S, Santa-Cruz D, Viswanathan S, Keating A. OCT4 expression mediates partial cardiomyocyte reprogramming of mesenchymal stromal cells. PLoS One. 2017;12(12):e0189131. https://doi.org/10.1371/journal.pone.0189131.CrossRefPubMedPubMedCentral

72.

Nagura S, Otaka S, Koike C, Okabe M, Yoshida T, Fathy M, et al. Effect of exogenous Oct4 overexpression on cardiomyocyte differentiation of human amniotic mesenchymal cells. Cell Reprogram. 2013;15(5):471–80. https://doi.org/10.1089/cell.2013.0002.CrossRefPubMed

73.

Sam J, Mercer EJ, Torregroza I, Banks KM, Evans T. Specificity, redundancy and dosage thresholds among gata4/5/6 genes during zebrafish cardiogenesis. Biol Open. 2020;9(6):bio053611. https://doi.org/10.1242/bio.053611.CrossRefPubMedPubMedCentral

74.

Laemmle LL, Cohen JB, Glorioso JC. Constitutive expression of GATA4 dramatically increases the cardiogenic potential of D3 mouse embryonic stem cells. Open. Biotechnol J. 2016;10:248–57. https://doi.org/10.2174/1874070701610010248.CrossRef

75.

Yamak A, Latinkic BV, Dali R, Temsah R, Nemer M. Cyclin D2 is a GATA4 cofactor in cardiogenesis. Proc Natl Acad Sci U S A. 2014;111(4):1415–20. https://doi.org/10.1073/pnas.1312993111.CrossRefPubMedPubMedCentral

76.

Liu J, Cheng H, Xiang M, Zhou L, Wu B, Moskowitz IP, et al. Gata4 regulates hedgehog signaling and Gata6 expression for outflow tract development. PLoS Genet. 2019;15(5):e1007711. https://doi.org/10.1371/journal.pgen.1007711.CrossRefPubMedPubMedCentral

77.

Lu F, Zhou Q, Liu L, Zeng G, Ci W, Liu W, et al. A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients. Theranostics. 2020;10(2):484–97. https://doi.org/10.7150/thno.38060.CrossRefPubMedPubMedCentral

78.

Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, et al. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J Exp Med. 2011;208(4):689–702. https://doi.org/10.1084/jem.20102099.CrossRefPubMedPubMedCentral

79.

Hellebrekers DM, Lentjes MH, van den Bosch SM, Melotte V, Wouters KA, Daenen KL, et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res. 2009;15(12):3990–7. https://doi.org/10.1158/1078-0432.CCR-09-0055.CrossRefPubMed

80.

Ma S, Xu Q, Shi R, Zhang X, Chen X. The omitted symptoms challenge the diagnosis of right atrial myxoma: a case report. BMC Cardiovasc Disord. 2020;20(1):149. https://doi.org/10.1186/s12872-020-01413-4.CrossRefPubMedPubMedCentral

81.

Amano J, Kono T, Wada Y, Zhang T, Koide N, Fujimori M, et al. Cardiac myxoma: its origin and tumor characteristics. Ann Thorac Cardiovasc Surg. 2003;9(4):215–21.PubMed

82.

Zhao T, Bai R, Wu F, Lu WJ, Zhang J. Generation of a TBX5 homozygous knockout embryonic stem cell line (WAe009-A-45) by CRISPR/Cas9 genome editing. Stem Cell Res. 2021;51:102156. https://doi.org/10.1016/j.scr.2021.102156.CrossRefPubMed

83.

Lahm H, Heinrich P, Zierler E, Dzilic E, Neb I, Luzius T, et al. Generation of a CRISPR/Cas edited human induced pluripotent stem cell line DHMi005-A-1 carrying a patient-specific disease-causing point mutation in the TBX5 gene. Stem Cell Res. 2022;60:102691. https://doi.org/10.1016/j.scr.2022.102691.CrossRefPubMed

84.

Anderson RH, Webb S, Brown NA, Lamers W, Moorman A. Development of the heart: (2) Septation of the atriums and ventricles. Heart. 2003;89(8):949–58. https://doi.org/10.1136/heart.89.8.949.CrossRefPubMedPubMedCentral

85.

Boogerd CJ, Dooijes D, Ilgun A, Mathijssen IB, Hordijk R, van de Laar IM, et al. Functional analysis of novel TBX5 T-box mutations associated with Holt-Oram syndrome. Cardiovasc Res. 2010;88(1):130–9. https://doi.org/10.1093/cvr/cvq178.CrossRefPubMed

86.

Goetz SC, Brown DD, Conlon FL. TBX5 is required for embryonic cardiac cell cycle progression. Development. 2006;133(13):2575–84. https://doi.org/10.1242/dev.02420.CrossRefPubMed

87.

Ghosh TK, Song FF, Packham EA, Buxton S, Robinson TE, Ronksley J, et al. Physical interaction between TBX5 and MEF2C is required for early heart development. Mol Cell Biol. 2009;29(8):2205–18. https://doi.org/10.1128/MCB.01923-08.CrossRefPubMedPubMedCentral

88.

Ma R, Yang Y, Tu Q, Hu K. Overexpression of T-box transcription factor 5 (TBX5) inhibits proliferation and invasion in non-small cell lung carcinoma cells. Oncol Res. 2017;25(9):1495–504. https://doi.org/10.3727/096504017X14883287513729.CrossRefPubMedPubMedCentral

89.

Misra C, Chang SW, Basu M, Huang N, Garg V. Disruption of myocardial Gata4 and Tbx5 results in defects in cardiomyocyte proliferation and atrioventricular septation. Hum Mol Genet. 2014;23(19):5025–35. https://doi.org/10.1093/hmg/ddu215.CrossRefPubMedPubMedCentral

90.

Mori AD, Bruneau BG. TBX5 mutations and congenital heart disease: Holt-Oram syndrome revealed. Curr Opin Cardiol. 2004;19(3):211–5. https://doi.org/10.1097/00001573-200405000-00004.CrossRefPubMed

91.

Fan C, Duhagon MA, Oberti C, Chen S, Hiroi Y, Komuro I, et al. Novel TBX5 mutations and molecular mechanism for Holt-Oram syndrome. J Med Genet. 2003;40(3):e29. https://doi.org/10.1136/jmg.40.3.e29.CrossRefPubMedPubMedCentral

92.

Fijnvandraat AC, Lekanne Deprez RH, Christoffels VM, Ruijter JM, Moorman AF. TBX5 overexpression stimulates differentiation of chamber myocardium in P19C16 embryonic carcinoma cells. J Muscle Res Cell Motil. 2003;24(2–3):211–8. https://doi.org/10.1023/a:1026063409656.CrossRefPubMed

93.

Snyder M, Huang XY, Zhang JJ. Stat3 directly controls the expression of Tbx5, Nkx2.5, and GATA4 and is essential for cardiomyocyte differentiation of P19CL6 cells. J Biol Chem. 2010;285(31):23639–46. https://doi.org/10.1074/jbc.M110.101063.CrossRefPubMedPubMedCentral

94.

Jia Y, Chang Y, Guo Z, Li H. Transcription factor Tbx5 promotes cardiomyogenic differentiation of cardiac fibroblasts treated with 5-azacytidine. J Cell Biochem. 2019;120(10):16503–15. https://doi.org/10.1002/jcb.28885.CrossRefPubMed

95.

Li Q, Guo ZK, Chang YQ, Yu X, Li CX, Li H. Gata4, Tbx5 and Baf60c induce differentiation of adipose tissue-derived mesenchymal stem cells into beating cardiomyocytes. Int J Biochem Cell Biol. 2015;66:30–6. https://doi.org/10.1016/j.biocel.2015.06.008.CrossRefPubMed

96.

Stirnimann CU, Ptchelkine D, Grimm C, Müller CW. Structural basis of TBX5-DNA recognition: the T-box domain in its DNA-bound and -unbound form. J Mol Biol. 2010;400(1):71–81. https://doi.org/10.1016/j.jmb.2010.04.052.CrossRefPubMed

97.

Peng C, Zhang WH, Pan B, Gao WQ, Tian J. Temporal regulation of transcription factor Mef2c by histone acetylases during cardiogenesis. Zhongguo Dang Dai Er Ke Za Zhi. 2014;16(4):418–23.PubMed

98.

Materna SC, Sinha T, Barnes RM, Lammerts van Bueren K, Black BL. Cardiovascular development and survival require Mef2c function in the myocardial but not the endothelial lineage. Dev Biol. 2019;445(2):170–7. https://doi.org/10.1016/j.ydbio.2018.12.002.CrossRefPubMed

99.

Vincentz JW, Barnes RM, Firulli BA, Conway SJ, Firulli AB. Cooperative interaction of Nkx2.5 and Mef2c transcription factors during heart development. Dev Dyn. 2008;237(12):3809–19. https://doi.org/10.1002/dvdy.21803.CrossRefPubMedPubMedCentral

100.

Torgersen JS, Takle H, Andersen Ø. Differential spatial expression of mef2 paralogs during cardiac development in Atlantic cod (Gadus morhua). Comp Biochem Physiol B Biochem Mol Biol. 2011;158(2):181–7. https://doi.org/10.1016/j.cbpb.2010.11.006.CrossRefPubMed

101.

Lei X, Zhao J, Sagendorf JM, Rajashekar N, Xu J, Dantas Machado AC, et al. Crystal structures of ternary complexes of MEF2 and NKX2-5 bound to DNA reveal a disease related protein-protein interaction Interface. J Mol Biol. 2020;432(19):5499–508. https://doi.org/10.1016/j.jmb.2020.07.004.CrossRefPubMedPubMedCentral

102.

Nenna A, Loreni F, Giacinto O, Chello C, Nappi P, Chello M, et al. miRNAs in cardiac Myxoma: new pathologic findings for potential therapeutic opportunities. Int J Mol Sci. 2022;23(6):3309. https://doi.org/10.3390/ijms23063309.CrossRefPubMedPubMedCentral

103.

Izarra A, Moscoso I, Cañón S, Carreiro C, Fondevila D, Martín-Caballero J, et al. miRNA-1 and miRNA-133a are involved in early commitment of pluripotent stem cells and demonstrate antagonistic roles in the regulation of cardiac differentiation. J Tissue Eng Regen Med. 2017;11(3):787–99. https://doi.org/10.1002/term.1977.CrossRefPubMed

104.

Kula-Alwar D, Marber MS, Hughes SM, Hinits Y. Mef2c factors are required for early but not late addition of cardiomyocytes to the ventricle. Dev Biol. 2021;470:95–107. https://doi.org/10.1016/j.ydbio.2020.11.008.CrossRefPubMedPubMedCentral

105.

Pane LS, Zhang Z, Ferrentino R, Huynh T, Cutillo L, Baldini A. Tbx1 is a negative modulator of Mef2c. Hum Mol Genet. 2012;21(11):2485–96. https://doi.org/10.1093/hmg/dds063.CrossRefPubMedPubMedCentral

106.

Okubo C, Narita M, Inagaki A, Nishikawa M, Hotta A, Yamanaka S, et al. Expression dynamics of HAND1/2 in in vitro human cardiomyocyte differentiation. Stem Cell Rep. 2021;16(8):1906–22. https://doi.org/10.1016/j.stemcr.2021.06.014.CrossRef

107.

Vincentz JW, Barnes RM, Firulli AB. Hand factors as regulators of cardiac morphogenesis and implications for congenital heart defects. Birth Defects Res A Clin Mol Teratol. 2011;91(6):485–94. https://doi.org/10.1002/bdra.20796.CrossRefPubMedPubMedCentral

108.

Witman N, Zhou C, Grote Beverborg N, Sahara M, Chien KR. Cardiac progenitors and paracrine mediators in cardiogenesis and heart regeneration. Semin Cell Dev Biol. 2020;100:29–51. https://doi.org/10.1016/j.semcdb.2019.10.011.CrossRefPubMed

109.

Koninckx R, Daniëls A, Windmolders S, Carlotti F, Mees U, Steels P, et al. Mesenchymal stem cells or cardiac progenitors for cardiac repair? A comparative study. Cell Mol Life Sci. 2011;68(12):2141–56. https://doi.org/10.1007/s00018-010-0560-y.CrossRefPubMed

110.

Orlandi A, Ciucci A, Ferlosio A, Genta R, Spagnoli LG, Gabbiani G. Cardiac myxoma cells exhibit embryonic endocardial stem cell features. J Pathol. 2006;209(2):231–9. https://doi.org/10.1002/path.1959.CrossRefPubMed

111.

Taubenschmid J, Weitzer G. Mechanisms of cardiogenesis in cardiovascular progenitor cells. Int Rev Cell Mol Biol. 2012;293:195–267. https://doi.org/10.1016/B978-0-12-394304-0.00012-9.CrossRefPubMed

112.

Sun Q, Taurin S, Sethakorn N, Long X, Imamura M, Wang DZ, et al. Myocardin-dependent activation of the CArG box-rich smooth muscle gamma-actin gene: preferential utilization of a single CArG element through functional association with the NKX3.1 homeodomain protein. J Biol Chem. 2009;284(47):32582–90. https://doi.org/10.1074/jbc.M109.033910.CrossRefPubMedPubMedCentral

113.

Wang N, Xu Y, Qin T, Wang FP, Ma LL, Luo XG, et al. Myocardin-related transcription factor-a is a key regulator in retinoic acid-induced neural-like differentiation of adult bone marrow-derived mesenchymal stem cells. Gene. 2013;523(2):178–86. https://doi.org/10.1016/j.gene.2013.03.043.CrossRefPubMed

114.

Zhang L, Wang H, Liu C, Wu Q, Su P, Wu D, et al. MSX2 initiates and accelerates mesenchymal stem/stromal cell specification of hPSCs by regulating TWIST1 and PRAME. Stem Cell Rep. 2018;11(2):497–513. https://doi.org/10.1016/j.stemcr.2018.06.019.CrossRef

115.

Chen YH, Ishii M, Sucov HM, Maxson RE Jr. Msx1 and Msx2 are required for endothelial-mesenchymal transformation of the atrioventricular cushions and patterning of the atrioventricular myocardium. BMC Dev Biol. 2008;8:75. https://doi.org/10.1186/1471-213X-8-75.CrossRefPubMedPubMedCentral

116.

Wu Q, Zhang L, Su P, Lei X, Liu X, Wang H, et al. MSX2 mediates entry of human pluripotent stem cells into mesendoderm by simultaneously suppressing SOX2 and activating NODAL signaling. Cell Res. 2015;25(12):1314–32. https://doi.org/10.1038/cr.2015.118.CrossRefPubMedPubMedCentral

117.

Jain R, Li D, Gupta M, Manderfield LJ, Ifkovits JL, Wang Q, et al. HEART DEVELOPMENT. Integration of bmp and Wnt signaling by Hopx specifies commitment of cardiomyoblasts. Science. 2015;348(6242):aaa6071. https://doi.org/10.1126/science.aaa6071.CrossRefPubMedPubMedCentral

118.

Chen F, Kook H, Milewski R, Gitler AD, Lu MM, Li J, et al. Hop is an unusual homeobox gene that modulates cardiac development. Cell. 2002;110(6):713–23. https://doi.org/10.1016/s0092-8674(02)00932-7.CrossRefPubMed

119.

Schneider MD, Baker AH, Riley P. Hopx and the Cardiomyocyte parentage. Mol Ther. 2015;23(9):1420–2. https://doi.org/10.1038/mt.2015.140.CrossRefPubMedPubMedCentral

120.

Li D, Sun J, Zhong TP. Wnt signaling in heart development and regeneration. Curr Cardiol Rep. 2022; https://doi.org/10.1007/s11886-022-01756-8.

121.

Pahnke A, Conant G, Huyer LD, Zhao Y, Feric N, Radisic M. The role of Wnt regulation in heart development, cardiac repair and disease: a tissue engineering perspective. Biochem Biophys Res Commun. 2016;473(3):698–703.CrossRefPubMed

122.

Tian Y, Cohen ED, Morrisey EE. The importance of Wnt signaling in cardiovascular development. Pediatr Cardiol. 2010;31(3):342–8. https://doi.org/10.1007/s00246-009-9606-z.CrossRefPubMed

123.

Flaherty MP, Kamerzell TJ, Dawn B. Wnt signaling and cardiac differentiation. Prog Mol Biol Transl Sci. 2012;111:153–74. https://doi.org/10.1016/B978-0-12-398459-3.00007-1.CrossRefPubMed

124.

Cohen ED, Miller MF, Wang Z, Moon RT, Morrisey EE. Wnt5a and Wnt11 are essential for second heart field progenitor development. Development. 2012;139(11):1931–40. https://doi.org/10.1242/dev.069377.CrossRefPubMedPubMedCentral

125.

Du Q, Geller DA. Cross-regulation between Wnt and NF-κB signaling pathways. For Immunopathol Dis Therap. 2010;1(3):155–81. https://doi.org/10.1615/ForumImmunDisTher.v1.i3.CrossRefPubMedPubMedCentral

126.

Park EJ, Watanabe Y, Smyth G, Miyagawa-Tomita S, Meyers E, Klingensmith J, et al. An FGF autocrine loop initiated in second heart field mesoderm regulates morphogenesis at the arterial pole of the heart. Development. 2008;135(21):3599–610. https://doi.org/10.1242/dev.025437.CrossRefPubMed

127.

Zhang J, Tao R, Campbell KF, Carvalho JL, Ruiz EC, Kim GC, et al. Functional cardiac fibroblasts derived from human pluripotent stem cells via second heart field progenitors. Nat Commun. 2019;10(1):2238. https://doi.org/10.1038/s41467-019-09831-5.CrossRefPubMedPubMedCentral

128.

Khosravi F, Ahmadvand N, Bellusci S, Sauer H. The multifunctional contribution of FGF signaling to cardiac development, homeostasis, disease and repair. Front Cell Dev Biol. 2021;9:672935. https://doi.org/10.3389/fcell.2021.672935.CrossRefPubMedPubMedCentral

129.

Bosada FM, Devasthali V, Jones KA, Stankunas K. Wnt/β-catenin signaling enables developmental transitions during valvulogenesis. Development. 2016;143(6):1041–54. https://doi.org/10.1242/dev.130575.CrossRefPubMedPubMedCentral

130.

Rosenblatt-Velin N, Lepore MG, Cartoni C, Beermann F, Pedrazzini T. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest. 2005;115(7):1724–33. https://doi.org/10.1172/JCI23418.CrossRefPubMedPubMedCentral

131.

Tahara N, Akiyama R, Wang J, Kawakami H, Bessho Y, Kawakami Y. The FGF-AKT pathway is necessary for cardiomyocyte survival for heart regeneration in zebrafish. Dev Biol. 2021;472:30–7. https://doi.org/10.1016/j.ydbio.2020.12.019.CrossRefPubMedPubMedCentral

132.

Kiyonari H, Kaneko M, Abe S, Aizawa S. Three inhibitors of FGF receptor, ERK, and GSK3 establishes germline-competent embryonic stem cells of C57BL/6N mouse strain with high efficiency and stability. Genesis. 2010;48(5):317–27. https://doi.org/10.1002/dvg.20614.CrossRefPubMed

133.

Fujisawa H, Koide N, Kono T, Takayama K, Tsukioka K, Wada Y, et al. Expression of basic fibroblast growth factor and its receptor-1 in cardiac myxoma. J Cardiovasc Surg. 2002;43(5):589–94.

134.

Liao S, Bodmer JR, Azhar M, Newman G, Coffin JD, Doetschman T, et al. The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury. J Mol Cell Cardiol. 2010;48(6):1245–54. https://doi.org/10.1016/j.yjmcc.2010.01.014.CrossRefPubMed

135.

Marques SR, Yelon D. Differential requirement for BMP signaling in atrial and ventricular lineages establishes cardiac chamber proportionality. Dev Biol. 2009;328(2):472–82. https://doi.org/10.1016/j.ydbio.2009.02.010.CrossRefPubMedPubMedCentral

136.

van Wijk B, Moorman AF, van den Hoff MJ. Role of bone morphogenetic proteins in cardiac differentiation. Cardiovasc Res. 2007;74(2):244–55. https://doi.org/10.1016/j.cardiores.2006.11.022.CrossRefPubMed

137.

Bin Z, Sheng LG, Gang ZC, Hong J, Jun C, Bo Y, et al. Efficient cardiomyocyte differentiation of embryonic stem cells by bone morphogenetic protein-2 combined with visceral endoderm-like cells. Cell Biol Int. 2006;30(10):769–76. https://doi.org/10.1016/j.cellbi.2006.05.011.CrossRefPubMed

138.

Pashmforoush M, Lu JT, Chen H, Amand TS, Kondo R, Pradervand S, et al. Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. Cell. 2004;117(3):373–86. https://doi.org/10.1016/s0092-8674(04)00405-2.CrossRefPubMed

139.

Lien CL, McAnally J, Richardson JA, Olson EN. Cardiac-specific activity of an Nkx2-5 enhancer requires an evolutionarily conserved Smad binding site. Dev Biol. 2002;244(2):257–66. https://doi.org/10.1006/dbio.2002.0603.CrossRefPubMed

140.

Gude N, Joyo E, Toko H, Quijada P, Villanueva M, Hariharan N, et al. Notch activation enhances lineage commitment and protective signaling in cardiac progenitor cells. Basic Res Cardiol. 2015;110(3):29. https://doi.org/10.1007/s00395-015-0488-3.CrossRefPubMedPubMedCentral

141.

Gude N, Sussman M. Notch signaling and cardiac repair. J Mol Cell Cardiol. 2012;52(6):1226–32. https://doi.org/10.1016/j.yjmcc.2012.03.007.CrossRefPubMedPubMedCentral

142.

Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678–89. https://doi.org/10.1038/nrm2009.CrossRefPubMed

143.

Miao L, Lu Y, Nusrat A, Abdelnasser HY, Datta S, Zhou B, et al. The spatiotemporal expression of Notch1 and numb and their functional interaction during cardiac morphogenesis. Cells. 2021;10(9):2192. https://doi.org/10.3390/cells10092192.CrossRefPubMedPubMedCentral

144.

Timmerman LA, Grego-Bessa J, Raya A, Bertrán E, Pérez-Pomares JM, Díez J, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004;18(1):99–115. https://doi.org/10.1101/gad.276304.CrossRefPubMedPubMedCentral

145.

Papoutsi T, Luna-Zurita L, Prados B, Zaffran S, de la Pompa JL. Bmp2 and notch cooperate to pattern the embryonic endocardium. Development. 2018;145(13):dev163378. https://doi.org/10.1242/dev.163378.CrossRefPubMed

146.

de la Pompa JL, Epstein JA. Coordinating tissue interactions: notch signaling in cardiac development and disease. Dev Cell. 2012;22(2):244–54. https://doi.org/10.1016/j.devcel.2012.01.014.CrossRefPubMedPubMedCentral

147.

Pitsava G, Zhu C, Sundaram R, Mills JL, Stratakis CA. Predicting the risk of cardiac myxoma in Carney complex. Genet Med. 2021;23(1):80–5. https://doi.org/10.1038/s41436-020-00956-3.CrossRefPubMed

148.

Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab. 2001;86(9):4041–6. https://doi.org/10.1210/jcem.86.9.7903.CrossRefPubMed

149.

Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, et al. Mutations of the gene encoding the protein kinase a type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet. 2000;26(1):89–92. https://doi.org/10.1038/79238.CrossRefPubMed

150.

Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5′-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab. 2009;94(6):2085–91. https://doi.org/10.1210/jc.2008-2333.CrossRefPubMedPubMedCentral

151.

Briassoulis G, Kuburovic V, Xekouki P, Patronas N, Keil MF, Lyssikatos C, et al. Recurrent left atrial myxomas in Carney complex: a genetic cause of multiple strokes that can be prevented. J Stroke Cerebrovasc Dis. 2012;21(8):914.e1–8. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.01.006.CrossRefPubMed

152.

Hashimoto H, Wang Z, Garry GA, Malladi VS, Botten GA, Ye W, et al. Cardiac reprogramming factors synergistically activate genome-wide cardiogenic stage-specific enhancers. Cell Stem Cell. 2019;25(1):69–86.e5. https://doi.org/10.1016/j.stem.2019.03.022.CrossRefPubMedPubMedCentral

153.

Lozano-Velasco E, Garcia-Padilla C, Del Mar Muñoz-Gallardo M, Martinez-Amaro FJ, Caño-Carrillo S, Castillo-Casas JM, et al. Post-transcriptional regulation of molecular determinants during Cardiogenesis. Int J Mol Sci. 2022;23(5):2839. https://doi.org/10.3390/ijms23052839.CrossRefPubMedPubMedCentral

154.

Yu MS, Spiering S, Colas AR. Generation of first heart field-like cardiac progenitors and ventricular-like Cardiomyocytes from human pluripotent stem cells. J Vis Exp. 2018;136:57688. https://doi.org/10.3791/57688.CrossRef

155.

Zhang L, Nomura-Kitabayashi A, Sultana N, Cai W, Cai X, Moon AM, et al. Mesodermal Nkx2.5 is necessary and sufficient for early second heart field development. Dev Biol. 2014;390(1):68–79. https://doi.org/10.1016/j.ydbio.2014.02.023.CrossRefPubMedPubMedCentral

156.

George V, Colombo S, Targoff KL. An early requirement for nkx2.5 ensures the first and second heart field ventricular identity and cardiac function into adulthood. Dev Biol. 2015;400(1):10–22. https://doi.org/10.1016/j.ydbio.2014.12.019.CrossRefPubMed

157.

Shouman S, Zaher A, Abdelhameed A, Elshaboury S, Sakr S, Fouda BE, et al. Cardiac Progenitor Cells. Adv Exp Med Biol. 2021;1312:51–73. https://doi.org/10.1007/5584_2020_594.CrossRefPubMed

158.

Arbatlı S, Aslan GS, Kocabaş F. Stem cells in regenerative cardiology. Adv Exp Med Biol. 2018;1079:37–53. https://doi.org/10.1007/5584_2017_113.CrossRefPubMed

159.

Piven OO, Winata CL. The canonical way to make a heart: β-catenin and plakoglobin in heart development and remodeling. Exp Biol Med. 2017;242(18):1735–45. https://doi.org/10.1177/1535370217732737.CrossRef

160.

Zhang Y, Wang L, Gao P, Sun Z, Li N, Lu Y, et al. ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells. Int J Mol Med. 2018;42(5):2343–52. https://doi.org/10.3892/ijmm.2018.3842.CrossRefPubMedPubMedCentral

161.

Alshalalfa M, Abou-Ouf H, Davicioni E, Karnes RJ, Alhajj R, Bismar TA. Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation. J Cancer Res Clin Oncol. 2021;147(8):2223–31. https://doi.org/10.1007/s00432-021-03634-2.CrossRefPubMed

162.

Li L, Sun F, Chen X, Zhang M. ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis. OncoTargets Ther. 2018;11:781–9. https://doi.org/10.2147/OTT.S144241.CrossRef

163.

Li M, Sun C, Bu X, Que Y, Zhang L, Zhang Y, et al. ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma. Cell Death Dis. 2021;12(6):620. https://doi.org/10.1038/s41419-021-03894-3.CrossRefPubMedPubMedCentral

164.

Shi Q, Wang W, Jia Z, Chen P, Ma K, Zhou C. ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth. Oncotarget. 2016;7(24):36489–500. https://doi.org/10.18632/oncotarget.9269.CrossRefPubMedPubMedCentral

165.

Alfert A, Moreno N, Kerl K. The BAF complex in development and disease. Epigenetics Chromatin. 2019;12(1):19. https://doi.org/10.1186/s13072-019-0264-y.CrossRefPubMedPubMedCentral

166.

Mittal P, Roberts CWM. The SWI/SNF complex in cancer - biology, biomarkers and therapy. Nat Rev Clin Oncol. 2020;17(7):435–48. https://doi.org/10.1038/s41571-020-0357-3.CrossRefPubMedPubMedCentral

167.

Nakashima Y, Yanez DA, Touma M, Nakano H, Jaroszewicz A, Jordan MC, et al. Nkx2-5 suppresses the proliferation of atrial myocytes and conduction system. Circ Res. 2014;114(7):1103–13. https://doi.org/10.1161/CIRCRESAHA.114.303219.CrossRefPubMed

168.

Nagel S, Kaufmann M, Drexler HG, MacLeod RA. The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res. 2003;63(17):5329–34.PubMed

169.

Penha RCC, Buexm LA, Rodrigues FR, de Castro TP, Santos MCS, Fortunato RS, et al. NKX2.5 is expressed in papillary thyroid carcinomas and regulates differentiation in thyroid cells. BMC Cancer. 2018;18(1):498. https://doi.org/10.1186/s12885-018-4399-1.CrossRefPubMedPubMedCentral

170.

Kojic S, Nestorovic A, Rakicevic L, Protic O, Jasnic-Savovic J, Faulkner G, et al. Cardiac transcription factor Nkx2.5 interacts with p53 and modulates its activity. Arch Biochem Biophys. 2015;569:45–53. https://doi.org/10.1016/j.abb.2015.02.001.CrossRefPubMed

171.

Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, et al. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One. 2008;3(4):e2079. https://doi.org/10.1371/journal.pone.0002079.CrossRefPubMedPubMedCentral

172.

Moussa H, Sidhom I. NKX2-5, SIL/TAL and TLX3/HOX11L2 expression in Egyptian pediatric T-cell acute lymphoblastic leukemia. Asia Pac J Clin Oncol. 2016;12(1):e1–10. https://doi.org/10.1111/ajco.12119.CrossRefPubMed

173.

Przybylski GK, Dik WA, Grabarczyk P, Wanzeck J, Chudobska P, Jankowski K, et al. The effect of a novel recombination between the homeobox gene NKX2-5 and the TRD locus in T-cell acute lymphoblastic leukemia on activation of the NKX2-5 gene. Haematologica. 2006;91(3):317–21.PubMed

174.

Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–83. https://doi.org/10.1200/JCO.2016.70.7836.CrossRefPubMedPubMedCentral

175.

Välimäki MJ, Ruskoaho HJ. Targeting GATA4 for cardiac repair. IUBMB Life. 2020;72(1):68–79. https://doi.org/10.1002/iub.2150.CrossRefPubMed

176.

Katanasaka Y, Suzuki H, Sunagawa Y, Hasegawa K, Morimoto T. Regulation of cardiac transcription factor GATA4 by post-translational modification in Cardiomyocyte hypertrophy and heart failure. Int Heart J. 2016;57(6):672–5. https://doi.org/10.1536/ihj.16-404.CrossRefPubMed

177.

Dai YS, Cserjesi P, Markham BE, Molkentin JD. The transcription factors GATA4 and dHAND physically interact to synergistically activate cardiac gene expression through a p300-dependent mechanism. J Biol Chem. 2002;277(27):24390–8. https://doi.org/10.1074/jbc.M202490200.CrossRefPubMed

178.

Patel RS, Romero R, Watson EV, Liang AC, Burger M, Westcott PMK, et al. A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells. Nat Commun. 2022;13(1):256. https://doi.org/10.1038/s41467-021-27731-5.CrossRefPubMedPubMedCentral

179.

Soini T, Haveri H, Elo JM, Kauppinen M, Kyrönlahti A, Salo MK, et al. Transcription factor GATA-4 is abundantly expressed in childhood but not in adult liver tumors. J Pediatr Gastroenterol Nutr. 2012;54(1):101–8. https://doi.org/10.1097/MPG.0b013e31822d52cf.CrossRefPubMed

180.

Cai KQ, Caslini C, Capo-chichi CD, Slater C, Smith ER, Wu H, et al. Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia. PLoS One. 2009;4(7):e6454. https://doi.org/10.1371/journal.pone.0006454.CrossRefPubMedPubMedCentral

181.

Han Q, Xu X, Li J, Wang J, Bai L, Wang A, et al. GATA4 is highly expressed in childhood acute lymphoblastic leukemia, promotes cell proliferation and inhibits apoptosis by activating BCL2 and MDM2. Mol Med Rep. 2017;16(5):6290–8. https://doi.org/10.3892/mmr.2017.7369.CrossRefPubMed

182.

Khalid AB, Pence J, Suthon S, Lin J, Miranda-Carboni GA, Krum SA. GATA4 regulates mesenchymal stem cells via direct transcriptional regulation of the WNT signalosome. Bone. 2021;144:115819. https://doi.org/10.1016/j.bone.2020.115819.CrossRefPubMed

183.

Behiry EG, Al-Azzouny MA, Sabry D, Behairy OG, Salem NE. Association of NKX2-5, GATA4, and TBX5 polymorphisms with congenital heart disease in Egyptian children. Mol Genet Genomic Med. 2019;7(5):e612. https://doi.org/10.1002/mgg3.612.CrossRefPubMedPubMedCentral

184.

Dong MJ, Zhou Y, Duan M, Gao QM, Zhao JH. Clinical significance and mechanism of TBX5 gene in colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2020;42(5):383–90. https://doi.org/10.3760/cma.j.cn112152-112152-20190829-00560.CrossRefPubMed

185.

Yu J, Ma X, Cheung KF, Li X, Tian L, Wang S, et al. Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer. Oncogene. 2010;29(49):6464–74. https://doi.org/10.1038/onc.2010.370.CrossRefPubMed

186.

Cheng L, Han T, Chen B, Nie K, Peng W. TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma. BMC Cancer. 2021;21(1):794. https://doi.org/10.1186/s12885-021-08517-w.CrossRefPubMedPubMedCentral

187.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, et al. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's oncology group. J Hematol Oncol. 2015;8:115. https://doi.org/10.1186/s13045-015-0215-4.CrossRefPubMedPubMedCentral

188.

Canté-Barrett K, Pieters R, Meijerink JP. Myocyte enhancer factor 2C in hematopoiesis and leukemia. Oncogene. 2014;33(4):403–10. https://doi.org/10.1038/onc.2013.56.CrossRefPubMed

189.

Vitali C, Bassani C, Chiodoni C, Fellini E, Guarnotta C, Miotti S, et al. SOCS2 controls proliferation and Stemness of hematopoietic cells under stress conditions and its deregulation Marks unfavorable acute Leukemias. Cancer Res. 2015;75(11):2387–99. https://doi.org/10.1158/0008-5472.CAN-14-3625.CrossRefPubMed

190.

Jingjing Z, Lei M, Jie Z, Sha C, Yapeng H, Weimin Z, et al. A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression. Naunyn Schmiedeberg's Arch Pharmacol. 2020;393(8):1549–58. https://doi.org/10.1007/s00210-019-01764-6.CrossRef

191.

Krenács D, Borbényi Z, Bedekovics J, Méhes G, Bagdi E, Krenács L. Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas. Virchows Arch. 2015;467(3):345–55. https://doi.org/10.1007/s00428-015-1796-6.CrossRefPubMed

192.

Pon JR, Wong J, Saberi S, Alder O, Moksa M, Grace Cheng SW, et al. MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation. Nat Commun. 2015;6:7953. https://doi.org/10.1038/ncomms8953.CrossRefPubMedPubMedCentral

193.

Da CM, Cheng ZY, Gong CY, Nan W, Zhou KS, Zhao GH, et al. Role of HAND2-AS1 in human tumors. Clin Chim Acta. 2020;511:189–97. https://doi.org/10.1016/j.cca.2020.10.020.CrossRefPubMed

194.

Jing GY, Zheng XZ, Ji XX. lncRNA HAND2-AS1 overexpression inhibits cancer cell proliferation in hepatocellular carcinoma by downregulating RUNX2 expression. J Clin Lab Anal. 2021;35(4):e23717. https://doi.org/10.1002/jcla.23717.CrossRefPubMedPubMedCentral

195.

Yuan Z, Yu X, Chen W, Chen D, Cai J, Jiang Y, et al. Epigenetic silencing and tumor suppressor gene of HAND2 by targeting ERK signaling in colorectal cancer. Cell Commun Signal. 2022;20(1):111. https://doi.org/10.1186/s12964-022-00878-4.CrossRefPubMedPubMedCentral

196.

Wang Y, Cai X. Long noncoding RNA HAND2-AS1 restrains proliferation and metastasis of breast cancer cells through sponging miR-1275 and promoting SOX7. Cancer Biomark. 2020;27(1):85–94. https://doi.org/10.3233/CBM-190530.CrossRefPubMed

197.

Zhang J, Ho JC, Chan YC, Lian Q, Siu CW, Tse HF. Overexpression of myocardin induces partial transdifferentiation of human-induced pluripotent stem cell-derived mesenchymal stem cells into cardiomyocytes. Physiol Rep. 2014;2(2):e00237. https://doi.org/10.1002/phy2.237.CrossRefPubMedPubMedCentral

198.

Tong X, Wang S, Lei Z, Li C, Zhang C, Su Z, et al. MYOCD and SMAD3/SMAD4 form a positive feedback loop and drive TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer. Oncogene. 2020;39(14):2890–904. https://doi.org/10.1038/s41388-020-1189-4.CrossRefPubMed

199.

Shats I, Milyavsky M, Cholostoy A, Brosh R, Rotter V. Myocardin in tumor suppression and myofibroblast differentiation. Cell Cycle. 2007;6(10):1141–6. https://doi.org/10.4161/cc.6.10.4251.CrossRefPubMed

200.

Taurin S, Sandbo N, Yau DM, Sethakorn N, Kach J, Dulin NO. Phosphorylation of myocardin by extracellular signal-regulated kinase. J Biol Chem. 2009;284(49):33789–94. https://doi.org/10.1074/jbc.M109.048983.CrossRefPubMedPubMedCentral

201.

Zhou Q, Chen W, Fan Z, Chen Z, Liang J, Zeng G, et al. Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer. Theranostics. 2021;11(13):6592–606. https://doi.org/10.7150/thno.59816.CrossRefPubMedPubMedCentral

202.

Medjkane S, Perez-Sanchez C, Gaggioli C, Sahai E, Treisman R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat Cell Biol. 2009;11(3):257–68. https://doi.org/10.1038/ncb1833.CrossRefPubMedPubMedCentral

203.

Martinez-Fernandez A, Nelson TJ, Ikeda Y, Terzic A. C-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells. J Cardiovasc Transl Res. 2010;3(1):13–23. https://doi.org/10.1007/s12265-009-9150-5.CrossRefPubMedPubMedCentral

204.

Wang H, Wang M, Wang Y, Wen Y, Chen X, Wu D, et al. MSX2 suppression through inhibition of TGFβ signaling enhances hematopoietic differentiation of human embryonic stem cells. Stem Cell Res Ther. 2020;11(1):147. https://doi.org/10.1186/s13287-020-01653-3.CrossRefPubMedPubMedCentral

205.

Satoh K, Hamada S, Kimura K, Kanno A, Hirota M, Umino J, et al. Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells. Am J Pathol. 2008;172(4):926–39. https://doi.org/10.2353/ajpath.2008.070346.CrossRefPubMedPubMedCentral

206.

Satoh K, Hamada S, Shimosegawa T. MSX2 in pancreatic tumor development and its clinical application for the diagnosis of pancreatic ductal adenocarcinoma. Front Physiol. 2012;3:430. https://doi.org/10.3389/fphys.2012.00430.CrossRefPubMedPubMedCentral

207.

Cheng SL, Behrmann A, Shao JS, Ramachandran B, Krchma K, Bello Arredondo Y, et al. Targeted reduction of vascular Msx1 and Msx2 mitigates arteriosclerotic calcification and aortic stiffness in LDLR-deficient mice fed diabetogenic diets. Diabetes. 2014;63(12):4326–37. https://doi.org/10.2337/db14-0326.CrossRefPubMedPubMedCentral

208.

Liu J, An H, Yuan W, Feng Q, Chen L, Ma J. Prognostic relevance and function of MSX2 in colorectal Cancer. J Diabetes Res. 2017;2017:3827037. https://doi.org/10.1155/2017/3827037.CrossRefPubMedPubMedCentral

209.

Wu Y, Jin Y, Yamamoto N, Takeuchi A, Miwa S, Tsuchiya H, et al. MSX2 inhibits the growth and migration of osteosarcoma cells by repressing SOX2. Am J Transl Res. 2021;13(6):5851–65.PubMedPubMedCentral

210.

Lallemand Y, Bensoussan V, Cloment CS, Robert B. Msx genes are important apoptosis effectors downstream of the Shh/Gli3 pathway in the limb. Dev Biol. 2009;331(2):189–98. https://doi.org/10.1016/j.ydbio.2009.04.038.CrossRefPubMed

211.

Kikuchi M, Katoh H, Waraya M, Tanaka Y, Ishii S, Tanaka T, et al. Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer. Cancer Lett. 2017;384:70–8. https://doi.org/10.1016/j.canlet.2016.10.017.CrossRefPubMed

212.

Yamashita K, Katoh H, Watanabe M. The homeobox only protein homeobox (HOPX) and colorectal cancer. Int J Mol Sci. 2013;14(12):23231–43. https://doi.org/10.3390/ijms141223231.CrossRefPubMedPubMedCentral

213.

Yap LF, Lai SL, Patmanathan SN, Gokulan R, Robinson CM, White JB, et al. HOPX functions as a tumour suppressor in head and neck cancer. Sci Rep. 2016;6:38758. https://doi.org/10.1038/srep38758.CrossRefPubMedPubMedCentral

214.

Pećina-Slaus N. Wnt signal transduction pathway and apoptosis: a review. Cancer Cell Int. 2010;10:22. https://doi.org/10.1186/1475-2867-10-22.CrossRefPubMedPubMedCentral

215.

Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4(5):a008052. https://doi.org/10.1101/cshperspect.a008052.CrossRefPubMedPubMedCentral

216.

Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma. 2008;55(3):165–76.PubMed

217.

Cohen ED, Tian Y, Morrisey EE. Wnt signaling: an essential regulator of cardiovascular differentiation, morphogenesis and progenitor self-renewal. Development. 2008;135(5):789–98. https://doi.org/10.1242/dev.016865.CrossRefPubMed

218.

Klaus A, Müller M, Schulz H, Saga Y, Martin JF, Birchmeier W. Wnt/β-catenin and bmp signals control distinct sets of transcription factors in cardiac progenitor cells. Proc Natl Acad Sci U S A. 2012;109(27):10921–6. https://doi.org/10.1073/pnas.1121236109.CrossRefPubMedPubMedCentral

219.

Cohen ED, Wang Z, Lepore JJ, Lu MM, Taketo MM, Epstein DJ, et al. Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. J Clin Invest. 2007;117(7):1794–804. https://doi.org/10.1172/JCI31731.CrossRefPubMedPubMedCentral

220.

Perry JM, He XC, Sugimura R, Grindley JC, Haug JS, Ding S, et al. Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev. 2011;25(18):1928–42. https://doi.org/10.1101/gad.17421911.CrossRefPubMedPubMedCentral

221.

Jiang YG, Luo Y, He DL, Li X, Zhang LL, Peng T, et al. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol. 2007;14(11):1034–9. https://doi.org/10.1111/j.1442-2042.2007.01866.x.CrossRefPubMed

222.

Tirosh-Finkel L, Zeisel A, Brodt-Ivenshitz M, Shamai A, Yao Z, Seger R, et al. BMP-mediated inhibition of FGF signaling promotes cardiomyocyte differentiation of anterior heart field progenitors. Development. 2010;137(18):2989–3000. https://doi.org/10.1242/dev.051649.CrossRefPubMed

223.

Wang J, Sontag D, Cattini PA. Heart-specific expression of FGF-16 and a potential role in postnatal cardioprotection. Cytokine Growth Factor Rev. 2015;26(1):59–66. https://doi.org/10.1016/j.cytogfr.2014.07.007.CrossRefPubMed

224.

Hu Y, Li L, Shen L, Gao H, Yu F, Yin W, et al. FGF-16 protects against adverse cardiac remodeling in the infarct diabetic heart. Am J Transl Res. 2017;9(4):1630–40.PubMedPubMedCentral

225.

Xu B, Li F, Zhang W, Su Y, Tang L, Li P, et al. Identification of metabolic pathways underlying FGF1 and CHIR99021-mediated cardioprotection. iScience. 2022;25(6):104447. https://doi.org/10.1016/j.isci.2022.104447.CrossRefPubMedPubMedCentral

226.

Chorianopoulos E, Heger T, Lutz M, Frank D, Bea F, Katus HA, et al. FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol. 2010;105(2):301–13. https://doi.org/10.1007/s00395-009-0046-y.CrossRefPubMed

227.

Novoyatleva T, Sajjad A, Pogoryelov D, Patra C, Schermuly RT, Engel FB. FGF1-mediated cardiomyocyte cell cycle reentry depends on the interaction of FGFR-1 and Fn14. FASEB J. 2014;28(6):2492–503. https://doi.org/10.1096/fj.13-243576.CrossRefPubMed

228.

Anderson DJ, Kaplan DI, Bell KM, Koutsis K, Haynes JM, Mills RJ, et al. NKX2-5 regulates human cardiomyogenesis via a HEY2 dependent transcriptional network. Nat Commun. 2018;9(1):1373. https://doi.org/10.1038/s41467-018-03714-x.CrossRefPubMedPubMedCentral

229.

Li J, Lv Y, Wang H, Liu Y, Ren J, Wang H. Cardiomyocyte-like cell differentiation by FGF-2 transfection and induction of rat bone marrow mesenchymal stem cells. Tissue Cell. 2021;73:101665. https://doi.org/10.1016/j.tice.2021.101665.CrossRefPubMed

230.

Ehata S, Miyazono K. Bone morphogenetic protein signaling in Cancer; some topics in the recent 10 years. Front Cell Dev Biol. 2022;10:883523. https://doi.org/10.3389/fcell.2022.883523.CrossRefPubMedPubMedCentral

231.

de Pater E, Ciampricotti M, Priller F, Veerkamp J, Strate I, Smith K, et al. Bmp signaling exerts opposite effects on cardiac differentiation. Circ Res. 2012;110(4):578–87. https://doi.org/10.1161/CIRCRESAHA.111.261172.CrossRefPubMedPubMedCentral

232.

Bach DH, Park HJ, Lee SK. The dual role of bone morphogenetic proteins in Cancer. Mol Ther Oncolytics. 2017;8:1–13. https://doi.org/10.1016/j.omto.2017.10.002.CrossRefPubMedPubMedCentral

233.

Langenfeld E, Deen M, Zachariah E, Langenfeld J. Small molecule antagonist of the bone morphogenetic protein type I receptors suppresses growth and expression of Id1 and Id3 in lung cancer cells expressing Oct4 or nestin. Mol Cancer. 2013;12(1):129. https://doi.org/10.1186/1476-4598-12-129.CrossRefPubMedPubMedCentral

234.

Fazeli Z, Omrani MD, Ghaderian SM. Down-regulation of nestin in mesenchymal stem cells derived from peripheral blood through blocking bone morphogenesis pathway. J Cell Commun Signal. 2016;10(4):273–82. https://doi.org/10.1007/s12079-016-0334-x.CrossRefPubMedPubMedCentral

235.

Karwacki-Neisius V, Göke J, Osorno R, Halbritter F, Ng JH, Weiße AY, et al. Reduced Oct4 expression directs a robust pluripotent state with distinct signaling activity and increased enhancer occupancy by Oct4 and Nanog. Cell Stem Cell. 2013;12(5):531–45. https://doi.org/10.1016/j.stem.2013.04.023.CrossRefPubMedPubMedCentral

236.

Ye L, Bokobza S, Li J, Moazzam M, Chen J, Mansel RE, et al. Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer. Cancer Sci. 2010;101(10):2137–44. https://doi.org/10.1111/j.1349-7006.2010.01648.x.CrossRefPubMed

237.

Sharma T, Kapoor A, Mandal CC. Duality of bone morphogenetic proteins in cancer: a comprehensive analysis. J Cell Physiol. 2022;237(8):3127–63. https://doi.org/10.1002/jcp.30785.CrossRefPubMed

238.

Zheng Y, Wang X, Wang H, Yan W, Zhang Q, Chang X. Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway. Tumour Biol. 2014;35(6):5189–98. https://doi.org/10.1007/s13277-014-1673-y.CrossRefPubMed

239.

Maegdefrau U, Bosserhoff AK. BMP activated Smad signaling strongly promotes migration and invasion of hepatocellular carcinoma cells. Exp Mol Pathol. 2012;92(1):74–81. https://doi.org/10.1016/j.yexmp.2011.10.004.CrossRefPubMed

240.

Maegdefrau U, Amann T, Winklmeier A, Braig S, Schubert T, Weiss TS, et al. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol. 2009;218(4):520–9. https://doi.org/10.1002/path.2563.CrossRefPubMed

241.

Moriyama H, Moriyama M, Ozawa T, Tsuruta D, Iguchi T, Tamada S, et al. Notch signaling enhances Stemness by regulating metabolic pathways through modifying p53, NF-κB, and HIF-1α. Stem Cells Dev. 2018;27(13):935–47. https://doi.org/10.1089/scd.2017.0260.CrossRefPubMed

242.

Nemir M, Pedrazzini T. Functional role of notch signaling in the developing and postnatal heart. J Mol Cell Cardiol. 2008;45(4):495–504. https://doi.org/10.1016/j.yjmcc.2008.02.273.CrossRefPubMed

243.

Wang Z, Da Silva TG, Jin K, Han X, Ranganathan P, Zhu X, et al. Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res. 2014;74(21):6364–74. https://doi.org/10.1158/0008-5472.CAN-14-2051.CrossRefPubMedPubMedCentral

244.

Kessler M, Hoffmann K, Brinkmann V, Thieck O, Jackisch S, Toelle B, et al. The notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids. Nat Commun. 2015;6:8989. https://doi.org/10.1038/ncomms9989.CrossRefPubMed

245.

Leucker TM, Bienengraeber M, Muravyeva M, Baotic I, Weihrauch D, Brzezinska AK, et al. Endothelial-cardiomyocyte crosstalk enhances pharmacological cardioprotection. J Mol Cell Cardiol. 2011;51(5):803–11. https://doi.org/10.1016/j.yjmcc.2011.06.026.CrossRefPubMedPubMedCentral

246.

Witman N, Murtuza B, Davis B, Arner A, Morrison JI. Recapitulation of developmental cardiogenesis governs the morphological and functional regeneration of adult newt hearts following injury. Dev Biol. 2011;354(1):67–76. https://doi.org/10.1016/j.ydbio.2011.03.021.CrossRefPubMed

247.

Bergmann O, Zdunek S, Felker A, Salehpour M, Alkass K, Bernard S, et al. Dynamics of cell generation and turnover in the human heart. Cell. 2015;161(7):1566–75. https://doi.org/10.1016/j.cell.2015.05.026.CrossRefPubMed

248.

Wagner JUG, Dimmeler S. Cellular cross-talks in the diseased and aging heart. J Mol Cell Cardiol. 2020;138:136–46. https://doi.org/10.1016/j.yjmcc.2019.11.152.CrossRefPubMed

249.

Hocker JD, Poirion OB, Zhu F, Buchanan J, Zhang K, Chiou J, et al. Cardiac cell type-specific gene regulatory programs and disease risk association. Sci Adv. 2021;7(20):eabf1444. https://doi.org/10.1126/sciadv.abf1444.CrossRefPubMedPubMedCentral

250.

de Soysa TY, Ranade SS, Okawa S, Ravichandran S, Huang Y, Salunga HT, et al. Single-cell analysis of cardiogenesis reveals basis for organ-level developmental defects. Nature. 2019;572(7767):120–4. https://doi.org/10.1038/s41586-019-1414-x.CrossRefPubMedPubMedCentral

251.

Li Y, Lin B, Yang L. Comparative transcriptomic analysis of multiple cardiovascular fates from embryonic stem cells predicts novel regulators in human cardiogenesis. Sci Rep. 2015;5:9758. https://doi.org/10.1038/srep09758.CrossRefPubMedPubMedCentral

252.

Mylonas KS, Ziogas IA, Avgerinos DV. Microenvironment in cardiac tumor development: what lies beyond the event horizon? Adv Exp Med Biol. 2020;1226:51–6. https://doi.org/10.1007/978-3-030-36214-0_4.CrossRefPubMed

253.

Cianflone E, Torella M, Biamonte F, De Angelis A, Urbanek K, Costanzo FS, et al. Targeting cardiac stem cell senescence to treat cardiac aging and disease. Cells. 2020;9(6):1558. https://doi.org/10.3390/cells9061558.CrossRefPubMedPubMedCentral

254.

Cianflone E, Torella M, Chimenti C, De Angelis A, Beltrami AP, Urbanek K, et al. Adult cardiac stem cell aging: a reversible stochastic phenomenon? Oxidative Med Cell Longev. 2019;2019:5813147. https://doi.org/10.1155/2019/5813147.CrossRef

255.

Ballard VL, Edelberg JM. Stem cells and the regeneration of the aging cardiovascular system. Circ Res. 2007;100(8):1116–27. https://doi.org/10.1161/01.RES.0000261964.19115.e3.CrossRefPubMed

256.

Shafi O. Inverse relationship between Alzheimer's disease and cancer, and other factors contributing to Alzheimer's disease: a systematic review. BMC Neurol. 2016;16(1):236. https://doi.org/10.1186/s12883-016-0765-2.CrossRefPubMedPubMedCentral

257.

Hariharan N, Sussman MA. Cardiac aging - getting to the stem of the problem. J Mol Cell Cardiol. 2015;83:32–6. https://doi.org/10.1016/j.yjmcc.2015.04.008.CrossRefPubMedPubMedCentral

258.

Aguilar-Sanchez C, Michael M, Pennings S. Cardiac stem cells in the postnatal heart: lessons from development. Stem Cells Int. 2018;2018:1247857. https://doi.org/10.1155/2018/1247857.CrossRefPubMedPubMedCentral

259.

Bergmann O, Jovinge S. Cardiac regeneration in vivo: mending the heart from within? Stem Cell Res. 2014;13(3 Pt B):523–31. https://doi.org/10.1016/j.scr.2014.07.002.CrossRefPubMed

260.

Pe'er D, Ogawa S, Elhanani O, Keren L, Oliver TG, Wedge D. Tumor heterogeneity. Cancer Cell. 2021;39(8):1015–7. https://doi.org/10.1016/j.ccell.2021.07.009.CrossRefPubMed

261.

Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105–17. https://doi.org/10.1016/j.bbcan.2009.11.002.CrossRefPubMed

262.

Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328–37. https://doi.org/10.1038/nature12624.CrossRefPubMedPubMedCentral

263.

Pietras A. Cancer stem cells in tumor heterogeneity. Adv Cancer Res. 2011;112:255–81. https://doi.org/10.1016/B978-0-12-387688-1.00009-0.CrossRefPubMed

264.

Li X, Martinez-Fernandez A, Hartjes KA, Kocher JP, Olson TM, Terzic A, et al. Transcriptional atlas of cardiogenesis maps congenital heart disease interactome. Physiol Genomics. 2014;46(13):482–95. https://doi.org/10.1152/physiolgenomics.00015.2014.CrossRefPubMedPubMedCentral

265.

Ameen M, Sundaram L, Shen M, Banerjee A, Kundu S, Nair S, et al. Integrative single-cell analysis of cardiogenesis identifies developmental trajectories and non-coding mutations in congenital heart disease. Cell. 2022;185(26):4937–4953.e23. https://doi.org/10.1016/j.cell.2022.11.028.CrossRefPubMed

266.

Yang D, Gomez-Garcia J, Funakoshi S, Tran T, Fernandes I, Bader GD, et al. Modeling human multi-lineage heart field development with pluripotent stem cells. Cell Stem Cell. 2022;29(9):1382–1401.e8. https://doi.org/10.1016/j.stem.2022.08.007.CrossRefPubMed

267.

Seeger T, Porteus M, Wu JC. Genome editing in cardiovascular biology. Circ Res. 2017;120(5):778–80. https://doi.org/10.1161/CIRCRESAHA.116.310197.CrossRefPubMedPubMedCentral

268.

Vermersch E, Jouve C, Hulot JS. CRISPR/Cas9 gene-editing strategies in cardiovascular cells. Cardiovasc Res. 2020;116(5):894–907. https://doi.org/10.1093/cvr/cvz250.CrossRefPubMed

269.

Jiang L, Liang J, Huang W, Ma J, Park KH, Wu Z, et al. Mol Ther. 2022;30(1):54–74. https://doi.org/10.1016/j.ymthe.2021.10.015.CrossRefPubMed

270.

Liu N, Olson EN. CRISPR modeling and correction of cardiovascular disease. Circ Res. 2022;130(12):1827–50. https://doi.org/10.1161/CIRCRESAHA.122.320496.CrossRefPubMedPubMedCentral

271.

Motta BM, Pramstaller PP, Hicks AA, Rossini A. The impact of CRISPR/Cas9 technology on cardiac research: from disease modelling to therapeutic approaches. Stem Cells Int. 2017;2017:8960236. https://doi.org/10.1155/2017/8960236.CrossRefPubMedPubMedCentral

272.

Marotta P, Cianflone E, Aquila I, Vicinanza C, Scalise M, Marino F, et al. Combining cell and gene therapy to advance cardiac regeneration. Expert Opin Biol Ther. 2018;18(4):409–23. https://doi.org/10.1080/14712598.2018.1430762.CrossRefPubMed

Title: The benign nature and rare occurrence of cardiac myxoma as a possible consequence of the limited cardiac proliferative/ regenerative potential: a systematic review
Authors: Ovais Shafi
Ghazia Siddiqui
Hassam A. Jaffry
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Cardiac Tumor
Cardiac Tumor
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11723-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Radiomic texture analysis based on neurite orientation dispersion and density imaging to differentiate glioblastoma from solitary brain metastasis

Evaluation of dynamic recurrence risk for locally advanced gastric cancer in the clinical setting of adjuvant chemotherapy: a real-world study with IPTW-based conditional recurrence analysis

Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms

Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas

Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)

Beneficial effects of alpha-1 antitrypsin therapy in a mouse model of colitis-associated colon cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer